Description

Milatuzumab is a humanized monoclonal antibody designed to target the CD74 antigen, a protein highly expressed on the surface of certain immune and cancer cells. This targeted mechanism makes it a critical reagent and investigational tool in the development of novel immunotherapies and diagnostic assays. It is primarily utilized by pharmaceutical R&D teams, biotechnology firms, and academic research institutions focused on oncology, autoimmune diseases, and B-cell malignancies. The compound, identified by CAS NO 899796-83-9, represents a high-purity biological entity essential for advancing precision medicine.

Application

• Research and Development of Targeted Cancer Therapies: Serves as a key reference standard and active pharmaceutical ingredient (API) in pre-clinical studies for B-cell cancers like non-Hodgkin lymphoma and multiple myeloma.
• Immuno-oncology Assay Development: Used to develop and validate diagnostic and pharmacodynamic assays, including flow cytometry, immunohistochemistry (IHC), and ELISA, to measure CD74 expression.
• Antibody-Drug Conjugate (ADC) Payload: Acts as the targeting moiety in the construction of novel ADCs, directing cytotoxic agents specifically to CD74-positive cells.
• Mechanism of Action Studies: Employed in vitro and in vivo to investigate CD74 signaling pathways, antibody-dependent cellular cytotoxicity (ADCC), and apoptosis induction.
• Biomarker Discovery and Validation: Utilized to characterize CD74 as a potential biomarker for patient stratification and treatment response monitoring in clinical trials.
• Production of Biosimilar Candidates: Provides a critical reference material for companies developing biosimilar versions of therapeutic antibodies targeting CD74.

Basic Information

Product Name	Milatuzumab
CAS No.	899796-83-9
Molecular Formula	C6472H10012N1732O2016S44
Molecular Weight	Approx. 145 kDa
Synonyms	hLL1; IMMU-115; Anti-CD74 monoclonal antibody hLL1; Humanized LL1 Antibody; CD74 Monoclonal Antibody (hLL1); IgG1, anti-(human CD74) (human-mouse monoclonal hLL1 γ1-chain), disulfide with human-mouse monoclonal hLL1 κ-chain, dimer; UNII-6V7V7MZ81N
EINECS	Contact for details

Quality Control

Our Milatuzumab is manufactured under strict quality systems to ensure batch-to-batch consistency and high biological activity. Each lot is subjected to a comprehensive battery of analytical tests, including SDS-PAGE and capillary electrophoresis for purity, size-exclusion HPLC for aggregate analysis, mass spectrometry for molecular weight confirmation, and functional binding assays (e.g., SPR, ELISA) to verify CD74 affinity. Certificates of Analysis (COA) detailing all specifications and test results are provided and available upon request.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized material at -20°C or below. Reconstituted solutions should be aliquoted and stored at -80°C to avoid repeated freeze-thaw cycles. This product is hygroscopic (moisture-sensitive); ensure containers are sealed under inert atmosphere or with desiccant when handling the lyophilized powder.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder
Identification (Mass Spec)	Consistent with theoretical molecular weight
Purity (SDS-PAGE, reduced & non-reduced)	≥ 95%
Monomer Content (SE-HPLC)	≥ 98%
Protein Content (UV A280)	≥ 1.0 mg/vial
Endotoxin (LAL)	< 1.0 EU/mg
Binding Activity (ELISA/SPR)	≥ 90% relative to reference standard
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.